Building a resilient antibiotic market An econometric modelling approach to estimating revenues for a novel, broad-spectrum intravenous antibiotic

Read full text Summarise with VIRAT
Authors: Leela Maitreyi, Sreenath Rajagopal, Anand Anandkumar, Santanu Datta
Cited by: 0
References: 33

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

India faces a mounting health crisis from antibiotic resistance, coupled with global pharmaceutical hesitancy to invest in novel antibiotic research and development (R&D), driven by complex scientific and financial hurdles. India carries one of the worlds largest absolute burdens of drug-resistant infections. The combination of a huge infectious-disease caseload, rapid urbanisation, and gaps in sanitation and primary care means that, when resistance emerges, it affects far more patients and generates a much larger pool of patients needing advanced antibiotics than in many high-income countries. Against this backdrop, demand for truly novel, broad-spectrum antibiotics in India is surging, fueled by rising multidrug-resistant infections, overstretched hospitals, and an antibiotic resistance market projected to grow rapidly over the next decade. Most countries respond with incentives and subscription models, for India, the answer lies in bold, innovative revenue strategies and in prioritising the domestic launch of novel antibiotics. This paper presents an econometric analysis of estimated valuation for a novel broad-spectrum antibiotic in India that, as a single therapeutic agent, can address several major hospital-acquired infections, including complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). The model focuses on a hypothetical ideal broad-spectrum intravenous antibiotic, and recommends that India pioneer market entry, highlighting financial models that maximise early revenues while still hardwiring stewardship. Launching new antibiotics first in India can catalyse robust real-world use, strengthen domestic pharma, and demonstrate that the economics of antibiotic innovation are viable. This decisive shift can transform India from a passive recipient of ageing drugs into the crucible where the next generation of life-saving antibiotics is forged, anchoring antibiotic research at the core of the countrys health security and economic resilience.

Fields of Study & Subjects

Pharmaceutical Economics and Policy Antibiotic Use and Resistance Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
medRxiv
Publication date
22 March 2026
Language
EN
Document type
Preprint